AbbVie Inc.

🇺🇸New York Stock Exchange
Back to all articles
AbbVie Inc. stock analysis ABBV overview
Bullish +65

Claris Financial LLC Makes New $1.79 Million Investment in AbbVie Inc ...

📈 Claris Financial LLC purchased a new stake of 7,840 shares in AbbVie valued at approximately $1.79 million during the fourth quarter.

📊 Several other institutional investors including Chelsea Counsel Co., Litman Gregory Wealth Management LLC, and Westend Capital Management LLC established new positions ranging from $26,000 to $31,000.

💰 AbbVie reported quarterly revenue of $15 billion, representing a 12.4% year-over-year increase that beat analyst estimates.

📉 The company posted earnings per share of $2.65, topping the consensus estimate of $2.59 by $0.06.

💵 AbbVie announced a quarterly dividend of $1.73 per share to be paid on August 14th with an ex-dividend date of July 15th.

📈 The stock currently trades at a PE ratio of 106.71 and has a market capitalization of $382.74 billion.

🔬 AbbVie's product portfolio covers major therapeutic categories including immunology, oncology, neuroscience, virology, and women's health.

Bullish Signals
  • AbbVie reported revenue of $15 billion for the quarter, which is a 12.4% increase compared to the previous year.
  • The company beat analyst earnings estimates with EPS of $2.65 versus a consensus of $2.59.
  • Institutional interest remains strong with hedge funds and other institutional investors owning 70.23% of the company's stock.
  • AbbVie has established a consistent dividend history, offering a yield of 3.2% on its recent quarterly payout.
  • The company successfully expanded its revenue base beyond analyst expectations of $14.72 billion.
Risk Factors
  • AbbVie's stock is trading below its 200-day moving average of $218.78, indicating potential short-term weakness relative to longer-term trends.
  • The company has a high payout ratio of 340.89%, which suggests the dividend is being paid from capital rather than current earnings.
Full Analysis
Claris Financial LLC increased its investment in AbbVie Inc. (NYSE: ABBV) during the fourth quarter by purchasing 7,840 shares valued at approximately $1.79 million. This acquisition represents about 1% of Claris's portfolio, making it the firm's 18th largest holding. Several other institutional investors also adjusted their positions recently, including Chelsea Counsel Co., Litman Gregory Wealth Management LLC, Westend Capital Management LLC, and Texas Capital Bancshares Inc., which all established new stakes ranging from $26,000 to $31,000. AbbVie reported strong quarterly financial results announced on April 29th, with revenue reaching $15 billion, a 12.4% year-over-year increase that surpassed analyst estimates of $14.72 billion. The company posted earnings per share of $2.65, beating the consensus estimate of $2.59 by $0.06. Analysts currently project full-year EPS of 14.3 for the current fiscal year. The stock recently opened at $216.63, trading above its 50-day moving average but below its 200-day moving average. The company has announced a quarterly dividend to be paid on August 14th for shareholders of record as of July 15th. The dividend amount is set at $1.73 per share, which annualizes to $6.92 and yields 3.2%. AbbVie, spun off from Abbott Laboratories in 2013, focuses on therapies for complex medical conditions across immunology, oncology, neuroscience, virology, and women's health sectors.